

Continuing to use this site you consent to the use of cookies on your device as described in our [Cookie Policy](#) unless you have disabled them. You can change your [Cookie Settings](#) at any time but parts of our site will not function correctly without them.

BS APPS BS PRODUCTS BS E-PAPER BS LEARNING

SIGN IN SUBSCRIBE

Business Standard

JUST IN States may face Rs 3 trillion GST compensation shortfall in FY22: Repor

Search News, Stock Quotes or Companie



You are here: [Home](#) » [Current Affairs](#) » [Coronavirus](#) » News


India's expert panel rejects Pfizer's application for Covid-19 vaccine

Cites serious adverse events

pics
Pfizer | Coronavirus Vaccine

Sohini Das | Mumbai
Last Updated at February 6, 2021 02:27 IST

Follow us on



Hide v Close

COVID-19

GLOBAL

CASES: 126,057,757





Pfizer on Friday said it had withdrawn its application, and would submit additional data as it becomes available in the near future

ALSO READ

India's Covid vaccine hope rolls over to 2021; panel to meet again on Jan 1

Next step on vaccines

Pfizer retracts request for emergency approval of Covid-19 vaccine in India

Decoded: What emergency use authorisation of Covid vaccine means for us

Govt inks pact, first consignment of Covid-19 vaccines to fly today

India's expert panel on Covid-19 drugs and vaccines has turned down US pharmaceutical major Pfizer's application for emergency use authorisation for its vaccine candidate -- already in use in the US and UK -- in the absence of any plan on the firm's part to generate safety and immunogenicity data in the local population.

Immunogenicity means the ability of a vaccine candidate to generate the desired immune response against the pathogen.

[Pfizer](#) on Friday said it had withdrawn its application, and would submit additional data as it becomes available in the near future.

India has insisted on having a safety and immunogenicity trial in the country. This became an important consideration for the expert panel, which noted that there had been several serious adverse events in the case of the Pfizer-BioNTech vaccine and the causality of these events was being investigated.

The company met the subject expert committee (SEC) on February 3. Sources revealed that the Indian drug regulator had decided to not allow emergency use approval for any vaccine candidate unless it was backed by data from a local bridge trial. "Safety and immunogenicity data from at least a 1,600-volunteer bridge trial in India is a must for the expert panel to recommend approval to any vaccine candidate," said a source in the know.

Hide v Close

SO READ: When will the Covid-19 pandemic end? in 7 years at today's vaccine rates

A spokesperson for Pfizer, however, said, "Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application. Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future."

The SEC noted, "The firm presented its proposal for emergency use authorisation of its Covid-19 mRNA vaccine, BNT162b, before the committee. The committee noted that incidents of palsy, anaphylaxis, and other serious adverse events (SAEs) have been reported during post marketing, and the causality of the events with the vaccine is being investigated. Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberations, the committee has not recommended for grant of permission for emergency use in the country at this stage."

FAILING THE REGULATORY TEST

▪ **Pfizer was the first pharma firm to seek emergency use authorisation** for its Covid vaccine from DCGI

On February 3, the expert committee deliberated on the firm's application

▪ **The panel noted serious adverse events, including palsy and anaphylaxis**

▪ **Causality of these events being investigated, it said; insisted on bridge trials in India**

▪ **India wants a 1,600-subject trial here to test safety and immune response**

▪ **Pfizer says may re-apply when it has additional data**

Earlier, the firm had missed appearing before the SEC thrice, blaming a short notice and time-zone difference for it.

The source added that Pfizer had also indicated there were no plans to manufacture the vaccine in India. "Pfizer's shipments have been falling globally, and the firm may have decided to focus on these geographies for the moment and increase production. To get approval in India, it would not only have to come back with data on facial palsy cases, but also with the clinical trial protocol for the bridge trial," said the source.

ALSO READ: More Covid-19 vaccine candidates get approval for clinical trials in India

The US administration is trying to order more Covid-19 vaccines from Pfizer and Moderna through the summer. These companies have to supply 100 million doses each to the US and will have to significantly increase the number of weekly doses they release to achieve that goal.

While it has withdrawn the application, the firm said Hide v Close committed to making the vaccine available for use in India.

"Pfizer remains committed to making its vaccine available for use by the government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," it said. Pfizer did not wish to comment on when it can re-apply for approval in India.

The vaccine requires refrigeration at minus 70 degree Celsius. The company had drawn up elaborate

u-chain plans for the same.

✉ Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and **subscribe to Business Standard.**

Digital Editor

Read our full coverage on Pfizer

First Published: Sat, February 06 2021. 02:19 IST

READ MORE ON CORONAVIRUS VACCINE CORONAVIRUS PFIZER

PREVIOUS STORY



The second wave: Many under-40s on long list of Covid-19 patients in Nagpur

NEXT STORY

Explained: How do the poor cope, struggle with road crashes in India?


GoAir's IPO Covid-19 face of log



Hide v

Close

RECOMMENDED FOR YOU



Beyond Business

GO

LATEST NEWS

IN THIS SECTION

ALL



Coronavirus LIVE: India records 62,291 new cases, 2nd wave worse than 1st



Key The second wave: Many under-40s on long list of Covid-19 patients in Nagpur



Key Explained: How do the poor cope, struggle with road crashes in India?



Key GoAir's IPO plan in midst of Covid-19 pandemic flies in the face of logic

Hide v

Close

Advertisement

More >

NEWS TRENDS 2020

[Coronavirus](#) [Coronavirus impact](#)
[India China Tensions](#) [Lockdown](#)
[Coronavirus Vaccine](#) [GlaxoSmithKline](#)
[Gold Price Today](#)
[Coronavirus State-Wise Tally](#) [DoT](#)
[Moratorium](#)

MOST POPULAR

READ

SHARE

COMMENTED



Tata vs Mistry: SC rules in favour of Tata Group, sets aside NCLAT order



Wabco India hits 20% upper circuit on strong response to OFS



World Coronavirus Dispatch: Can vaccine passports save travel industry?



Former RBI Deputy Governor K C Chakrabarti passes away in Mumbai

Advertisement

Hide v

Close



Hide ^v

Close

MORE ON MARKETS:

QUICK LINKS

- [STOCK MARKET LIVE](#)
- [STOCK MARKET NEWS](#)
- [PORTFOLIO](#)
- [DERIVATIVES](#)
- [COMMODITY MARKET](#)
- [MUTUAL FUNDS](#)
- [UPCOMING IPO](#)
- [GOLD PRICE](#)
- [PERSONAL FINANCE](#)
- [SENSEX](#)

BROWSE STOCK COMPANIES

[A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#)
[S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

[1](#) | [2](#) | [3](#) | [4](#) | [5](#) | [6](#) | [7](#) | [8](#) | [9](#)

BROWSE MUTUAL FUNDS

[A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#)
[S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

INDEX STOCKS

Adani Ports | Asian Paints | Axis Bank | B P C L | Bajaj Auto | Bajaj Finance Ltd | Bajaj Finserv | Bharti Airtel
 | Britannia Industries | Cipla | Coal India | Divi's Laboratories | Dr Reddy's Labs | Eicher Motors | GAIL (India) | Grasim Inds
 | HCL Technologies | H D F C | HDFC Bank | HDFC Life Insurance Company | Hero Motocorp | Hind. Unilever | Hindalco Inds.
 ICI Bank | Indian Oil Corporation Ltd. | IndusInd Bank | Infosys | ITC | JSW Steel | Kotak Mah. Bank | Larsen & Toubro
 & M | Maruti Suzuki | Nestle India Ltd. | NTPC | O N G C | Power Grid Corpn | Reliance Inds. | Shree Cement
 Bk of India | SBI Life Insurance | Sun Pharma. Inds. | Tata Motors | Tata Steel | TCS | Tech Mahindra | Titan Company
 | UltraTech Cement Ltd | UPL Ltd | Wipro

FROM BS WEBSITE

- [Home](#)
- [Companies](#)
- [Markets](#)
- [Opinion](#)
- [Politics](#)
- [Technology](#)
- [Specials](#)
- [Personal Finance](#)
- [Latest News](#)
- [Today's Paper](#)
- [RBI Policy](#)
- [General News](#)
- [General Videos](#)
- [General Photo Gallery](#)

ABOUT US

- [About Us](#)
- [Code of Conduct](#)
- [Terms & Conditions](#)
- [Privacy Policy](#)
- [Cookie Policy](#)
- [Disclaimer](#)
- [Investor Communication](#)
- [List of our GST registration number](#)

SUPPORT & CONTACT

- [Partner with Us](#)

READER CENTRE

- [Assistance](#)
- [E-Paper](#)
- [Manage My Account](#)
- [My Page](#)
- [Portfolio](#)
- [Register](#)
- [Subscribe](#)
- [Custom Payment](#)

BS PRODUCTS

- [Smart Investor](#)
- [BS Hindi](#)
- [BS Motoring](#)

BUDGET 2020

- [Elections 2020](#)
- [Lok Sabha Elections 2019](#)

SPORTS

- [Cricket](#)
- [Football](#)
- [ICC World Test Championship](#)
- [India vs Bangladesh](#)

[Hide v](#) [Close](#)

CONNECT WITH BS

- [Facebook](#)

EVENTS

- Authors
- Education

CAREERS

- Advertise with Us
- Contact Us
- Feedback
- Browser Support
- Sitemap

US BOOKS

- B2B Connect
- iPhone
- iPad
- android
- Mobile Browser

Telegram

Linkedin

Twitter

Youtube

RSS

EVENT

Insurance Round Table
2020



Hide v Close